Therefore, we further confirm that a combination of Afatinib and GW3965 simultaneously increases and activates LXR-α, resulting in an increase of tumor suppressors and, ultimately, tumor inhibition (Figure 5F). The gene discussed is NR1H3; the disease is neoplasm.